SCHEMBL25552109

SCHEMBL25552109

C[C@@H](OCc1ccccc1)[C@H](NC(=O)[C@@H](N)CCCCNC(=O)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.58
DPP8 Q6V1X1 3/20 0.55
DPP7 Q9UHL4 3/20 0.55
DPP4 P27487 2/20 0.52
DPP9 Q86TI2 2/20 0.52
CPB1 P15086 1/20 0.51
CPB2 Q96IY4 1/20 0.51
FOLH1 Q04609 2/20 0.49
SLC1A3 P43003 1/20 0.48
SLC1A1 P43005 1/20 0.48
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25552103 0.90 FOLH1 (0.51) ANPEPDPP8DPP7CPB1CPB2
SCHEMBL25552202 0.90 ANPEP (0.60) ANPEPDPP8DPP7DPP4DPP9
Hydrochloric Acid SCHEMBL10656757 0.85 ANPEP (0.62) ANPEPDPP8DPP7DPP4DPP9
Hydrochloric Acid SCHEMBL3831836 0.85 ANPEP (0.59) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL29942304 0.84 CPB1 (0.47) ANPEPCPB1CPB2FOLH1
Hydrochloric Acid SCHEMBL10655124 0.83 ANPEP (0.62) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL29832065 0.83 MAPT (0.57) CPB1CPB2FOLH1
SCHEMBL29831671 0.82 CPB1 (0.50) ANPEPCPB1CPB2FOLH1
SCHEMBL7318869 0.82 ANPEP (0.68) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL7321298 0.81 ANPEP (0.71) ANPEPDPP8DPP7DPP4DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-06-27 US disclosed
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-06-27 US disclosed
EP-4062974-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L BASE CO LTD (KR) 2024-05-08 EP disclosed
EP-4335452-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-03-13 EP disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
WO-2023043269-A1 PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE 주식회사 엘베이스 2023-03-23 WO disclosed
WO-2023043271-A1 METHOD FOR CHARACTERIZING RESPONDER TO CAGE INHIBITOR FOR CANCER THERAPY 주식회사 엘베이스 2023-03-23 WO disclosed
WO-2023043261-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG 주식회사 엘베이스 2023-03-23 WO disclosed
WO-2022203219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER 주식회사 엘베이스 2022-09-29 WO disclosed
EP-4062974-A2 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co.,Ltd. (KR) 2022-09-28 EP disclosed
WO-2022197100-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG 주식회사 엘베이스 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER VIP, QPCT, TPT1 ANPEP 24/4885DPP8 404/4885DPP7 236/4885
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG ALPG, SLC11A2, SGTA ANPEP 26/4885DPP8 1630/4885DPP7 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.